| Recruiting | A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Waldenström's Macroglobulinemia | Phase 4 | 2025-10-17 |
| Active Not Recruiting | A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Ac Rheumatoid Arthritis | Phase 2 | 2025-08-21 |
| Active Not Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Dos Chronic Spontaneous Urticaria | Phase 1 | 2025-07-19 |
| Completed | Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Particip Healthy Volunteers | Phase 1 | 2025-04-03 |
| Recruiting | A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | 2025-03-18 |
| Completed | A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Volunteers | Phase 1 | 2025-01-24 |
| Active Not Recruiting | A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participant Chronic Lymphocytic Leukemia, CLL | Phase 1 / Phase 2 | 2025-01-23 |
| Completed | A Study of Different Forms of BGB-43395 and Food Effect in Healthy Participants Healthy Volunteers | Phase 1 | 2025-01-14 |
| Recruiting | A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advan Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer | Phase 1 | 2024-11-26 |
| Recruiting | Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tu Advanced Solid Tumor | Phase 1 | 2024-10-18 |
| Terminated | A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic So Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer | Phase 1 | 2024-09-11 |
| Completed | A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers Not Determined | Phase 1 | 2024-08-19 |
| Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-A Healthy Participants, Healthy Subjects, Healthy Volunteers | Phase 1 | 2024-06-20 |
| Active Not Recruiting | BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and O Advanced Solid Tumor, Metastatic Solid Tumor, Hormone-receptor-positive Breast Cancer | Phase 1 | 2024-04-01 |
| Recruiting | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer | Phase 1 | 2024-03-11 |
| Withdrawn | Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Part Solid Tumors | Phase 1 | 2024-03-01 |
| Active Not Recruiting | Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Pa Non-small Cell Lung Cancer | Phase 1 | 2023-11-16 |
| Active Not Recruiting | A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectab Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma by AJCC V8 Stage | Phase 2 | 2023-11-08 |
| Completed | A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Sma Non-Small Cell Lung Cancer | Phase 2 | 2023-10-23 |
| Terminated | BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor | Phase 1 | 2023-08-21 |
| Active Not Recruiting | A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | 2023-07-21 |
| Terminated | A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Sol Advanced Solid Tumors | Phase 1 | 2023-07-19 |
| Withdrawn | Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Hepatocellular Carcinoma | Phase 3 | 2023-06-30 |
| Completed | A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417 Healthy Volunteers | Phase 1 | 2023-05-22 |
| Completed | Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunothera Non Small Cell Lung Cancer | Phase 2 | 2023-03-08 |
| Active Not Recruiting | A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Ca Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer | Phase 2 | 2023-03-07 |
| Completed | Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult Participants Healthy Volunteers | Phase 1 | 2023-03-07 |
| Recruiting | Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macrog Waldenstrom Macroglobulinemia | — | 2023-03-03 |
| Active Not Recruiting | A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plu Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | Phase 1 / Phase 2 | 2023-01-29 |
| Active Not Recruiting | A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combi Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma | Phase 1 / Phase 2 | 2023-01-09 |
| Active Not Recruiting | Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocyt Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | 2022-10-25 |
| Terminated | Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants Esophageal Squamous Cell Carcinoma | Phase 2 | 2022-10-03 |
| Active Not Recruiting | Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma | Phase 1 / Phase 2 | 2022-09-05 |
| Terminated | Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A Solid Tumor | Phase 1 | 2022-08-25 |
| Terminated | A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors Solid Tumor, Adult | Phase 1 | 2022-07-06 |
| Completed | Relative Bioavailability of Zanubrutinib Tablets Compared to Capsules and Effects of Food on the Pharmacokinet Healthy Volunteers | Phase 1 | 2022-06-07 |
| Completed | Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participan High-risk Neuroblastoma | Phase 1 | 2022-06-07 |
| Recruiting | Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted P B-cell Malignancy, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma | Phase 1 / Phase 2 | 2022-05-06 |
| Completed | Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | 2022-04-25 |
| Recruiting | A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refrac Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma | Phase 3 | 2022-03-10 |
| Withdrawn | Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects Healthy Volunteers | Phase 1 | 2022-02-17 |
| Completed | Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cance Colorectal Cancer | Phase 2 | 2022-01-26 |
| Completed | Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung C Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV | Phase 2 | 2021-11-16 |
| Completed | First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study of BGB-23339 in Healthy Participants Not Determined | Phase 1 | 2021-11-15 |
| Completed | To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Select Advanced Solid Tumor | Phase 2 | 2021-09-18 |
| Completed | A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Pati Advanced Hepatocellular Carcinoma | Phase 2 | 2021-08-20 |
| Completed | Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma Resectable Esophageal Squamous Cell Carcinoma | Phase 2 | 2021-08-17 |
| Completed | Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibi Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | Phase 2 | 2021-08-11 |
| Terminated | Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Ce Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | 2021-07-27 |
| Completed | Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Sma Limited Stage Small Cell Lung Cancer | Phase 2 | 2021-07-15 |
| Active Not Recruiting | Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies Mature B-cell Malignancies | Phase 1 | 2021-07-05 |
| Terminated | A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCR Non Small Cell Lung Cancer | Phase 3 | 2021-06-17 |
| Active Not Recruiting | A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer Non-small Cell Lung Cancer, NSCLC | Phase 3 | 2021-06-08 |
| Recruiting | A Study of BGB-11417 in Participants With Myeloid Malignancies Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm | Phase 1 / Phase 2 | 2021-05-24 |
| Completed | Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumor Advanced Solid Tumors | Phase 2 | 2021-04-19 |
| Completed | Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Esophageal Squamous Cell Carcinoma | Phase 2 | 2021-03-31 |
| Active Not Recruiting | BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanc Advanced Solid Tumor | Phase 1 | 2021-03-04 |
| Completed | AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monocl Cervical Cancer | Phase 2 | 2021-02-15 |
| Completed | Zanubrutinib in Participants With Active Proliferative Lupus Nephritis Lupus Nephritis | Phase 2 | 2020-12-22 |
| Terminated | Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma Classical Hodgkin Lymphoma | Phase 3 | 2020-12-14 |
| Completed | BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants Healthy | Phase 1 | 2020-12-09 |
| Completed | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants Covid19 | Phase 2 | 2020-12-02 |
| Completed | Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malign B-cell Malignancies | Phase 1 | 2020-11-15 |
| Completed | Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refrac Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | 2020-09-11 |
| Completed | Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 Covid19 | Phase 1 | 2020-09-08 |
| Completed | Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hep Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | Phase 2 | 2020-09-04 |
| Completed | Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma Classical Hodgkin Lymphoma | Phase 2 | 2020-08-20 |
| Completed | The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males Healthy, Male | Phase 1 | 2020-07-29 |
| Completed | Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults Tumor | Phase 1 | 2020-07-23 |
| Completed | Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants COVID-19 Pulmonary Complications, COVID-19 | Phase 2 | 2020-07-06 |
| Active Not Recruiting | Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cance Non Small Cell Lung Cancer | Phase 3 | 2020-05-29 |
| Completed | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | 2020-04-29 |
| Completed | Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislel Breast Cancer, Gastric Cancer, Gastroesophageal Junction Cancer | Phase 1 / Phase 2 | 2020-03-26 |
| Completed | Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advance Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 1 | 2020-01-30 |
| Completed | Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies Mature B-cell Malignancies | Phase 1 / Phase 2 | 2020-01-29 |
| Active Not Recruiting | Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies B-cell Malignancies | Phase 3 | 2020-01-16 |
| Completed | Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyr Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma | Phase 2 | 2019-10-15 |
| Active Not Recruiting | A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab i Mantle Cell Lymphoma; Non-Hodgkin Lymphoma | Phase 3 | 2019-08-20 |
| Completed | Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors Locally Advanced and Metastatic Solid Tumors | Phase 1 | 2019-08-15 |
| Completed | Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage S Small Cell Lung Cancer | Phase 3 | 2019-07-22 |
| Completed | A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | 2019-06-11 |
| Completed | Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With C Solid Tumor | Phase 1 | 2019-05-29 |
| Completed | Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advance Advanced Solid Tumors | Phase 1 | 2019-05-29 |
| Active Not Recruiting | Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Ur Urothelial Carcinoma | Phase 3 | 2019-05-29 |
| Completed | Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participant Solid Tumor, Adult | Phase 1 | 2019-05-01 |
| Completed | Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Ca Recurrent or Metastatic Nasopharyngeal Cancer | Phase 3 | 2019-03-27 |
| Completed | A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With U Carcinoma, Hepatocellular, Gastric/Gastroesophageal Junction Cancer | Phase 1 / Phase 2 | 2019-02-28 |
| Completed | Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma Marginal Zone Lymphoma, MZL | Phase 2 | 2019-02-19 |
| Terminated | Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency Metastatic Castration-Resistant Prostate Cancer (mCRPC), Homologous Recombination Deficiency (HRD) | Phase 2 | 2019-02-05 |
| Completed | Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advan Gastric, or Gastroesophageal Junction Adenocarcinoma | Phase 3 | 2018-12-13 |
| Completed | A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants Wi Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | 2018-12-11 |
| Completed | Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion | Phase 1 / Phase 2 | 2018-11-13 |
| Completed | A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocyt Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | 2018-11-01 |
| Completed | A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid T Advanced Solid Tumors | Phase 1 | 2018-11-01 |
| Recruiting | Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors MSI-H/dMMR Solid Tumors | Phase 2 | 2018-09-19 |
| Completed | A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer Non-Small Cell Lung Cancer | Phase 3 | 2018-07-30 |
| Completed | A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-sm Non-Small Cell Lung Cancer | Phase 3 | 2018-07-23 |
| Completed | Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer Advanced or Inoperable Gastric Cancer | Phase 2 | 2018-07-03 |
| Completed | Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA M HER2-negative Breast Cancer | Phase 2 | 2018-06-22 |
| Completed | A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in H Healthy Subjects | Phase 1 | 2018-06-07 |
| Completed | Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Funct Hepatic Insufficiency & Healthy Subjects | Phase 1 | 2018-05-30 |
| Active Not Recruiting | Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Ca Ovarian Cancer | Phase 3 | 2018-05-14 |
| Completed | Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma | Phase 2 | 2018-04-13 |
| Completed | Study of BGB-A317 in Participants With Previously Treated Unresectable HCC Hepatocellular Carcinoma (HCC) | Phase 2 | 2018-04-09 |
| Completed | A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | 2018-01-26 |
| Completed | A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib a Healthy Volunteers | Phase 1 | 2018-01-25 |
| Completed | BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymph Marginal Zone Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 2 | 2018-01-04 |
| Completed | A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) Hepatocellular Carcinoma (HCC) | Phase 3 | 2017-12-18 |
| Completed | Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or T Non-small Cell Lung Cancer | Phase 3 | 2017-11-30 |
| Terminated | Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors Advanced Solid Tumors | Phase 1 / Phase 2 | 2017-11-27 |
| Completed | A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma Relapsed/Refractory Follicular Non-Hodgkin Lymphoma | Phase 2 | 2017-11-14 |
| Active Not Recruiting | A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | 2017-10-31 |
| Completed | Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Health Healthy Volunteers: Asian, Non-Asian | Phase 1 | 2017-09-18 |
| Completed | Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia ( Waldenström's Macroglobulinemia (WM) | Phase 2 | 2017-08-31 |
| Completed | Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer Locally Advanced Lung Cancer; Metastatic Lung Cancer | Phase 2 | 2017-08-24 |
| Completed | BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma | Phase 2 | 2017-07-18 |
| Completed | Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Diffuse Large B-cell Lymphoma | Phase 2 | 2017-06-30 |
| Completed | Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) i Locally Advanced or Metastatic Solid Tumors | Phase 1 | 2017-06-28 |
| Completed | Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer Locally Advanced or Metastatic Urothelial Bladder Cancer | Phase 2 | 2017-06-16 |
| Completed | A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma Classical Hodgkin Lymphoma | Phase 2 | 2017-04-21 |
| Completed | Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males Healthy Volunteers | Phase 1 | 2017-03-29 |
| Completed | Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic L Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | Phase 2 | 2017-03-09 |
| Completed | Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymp Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma | Phase 2 | 2017-03-02 |
| Completed | A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) Waldenström's Macroglobulinemia | Phase 3 | 2017-01-25 |
| Completed | Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Program Advanced Solid Tumors | Phase 1 / Phase 2 | 2016-12-28 |
| Completed | Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Advanced High-grade Ovarian Cancer, Triple Negative Breast Cancer | Phase 1 / Phase 2 | 2016-12-21 |
| Completed | A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma B-cell Lymphoma | Phase 1 | 2016-07-05 |
| Completed | Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies Lymphoma, Leukemia | Phase 1 | 2016-06-29 |
| Completed | Study to Evaluate the Effect of Food on the Pharmacokinetics of a BGB-3111 in Healthy Subjects Healthy Volunteers | Phase 1 | 2016-05-25 |
| Completed | The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants Wi Solid Tumors | Phase 1 | 2016-02-02 |
| Completed | BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies B-cell Lymphoid Malignancies | Phase 1 | 2016-01-13 |
| Completed | The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor Solid Tumors | Phase 1 | 2015-10-12 |
| Completed | Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumor Advanced Cancer | Phase 1 | 2015-06-02 |
| Completed | Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies B-cell Malignancies | Phase 1 / Phase 2 | 2014-09-04 |
| Completed | Phase 1a/1b BGB-290 for Advanced Solid Tumors. For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment | Phase 1 | 2014-07-03 |
| Completed | Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors Solid Tumors | Phase 1 | 2013-11-20 |
| No Longer Available | A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies Waldenström Macroglobulinemia | — | — |